文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV感染者2型糖尿病后肾脏与心血管并发症风险

Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024.
PubMed 文献 · Clin Infect Dis · 2026-01-01

HIV感染者主要肾脏不良事件风险显著升高(adjHR 2.04,95%CI 1.57-2.65),心血管事件风险与全因死亡无显著增加。

要点

  • HIV感染者2型糖尿病后主要肾脏不良事件风险约为非感染者的2倍
  • BMI≥30 kg/m²的HIV感染者肾脏风险尤为突出

核心结论

  • HIV合并2型糖尿病者肾脏并发症风险高于非HIV感染者,提示可能需要加强肾脏监测。

研究设计与样本

  • 瑞典全国性队列研究,纳入1930-2006年出生、2010-2019年诊断2型糖尿病的居民。
  • 采用Cox回归按HIV状态估计风险比,并按倾向评分五分位分层。

主要发现

  • HIV感染者主要肾脏不良事件校正风险比2.04(95%CI 1.57-2.65)。
  • 全因死亡风险无显著增加。
  • 排除基线使用富马酸替诺福韦二吡呋酯者及竞争风险模型结果一致。
  • 校正 bictegravir、cobicistat、dolutegravir、rilpivirine 相关血肌酐良性升高后肾脏风险仍存在但无统计学显著性。

临床怎么用

  • 对HIV合并2型糖尿病者应加强肾脏功能监测。
  • 关注BMI≥30 kg/m²的HIV合并2型糖尿病者的肾脏风险。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes mellitus (T2DM) is common among people with HIV (PWH), although studies comparing T2DM-related complications in people with and without HIV (PWoH) remain limited. This was assessed using data from the Cohort Study on Morbidity and HIV in Sweden (COSMOHS). METHODS: Nationwide study including Swedish residents born 1930-2006, diagnosed with T2DM between 2010 and 2019, followed until 31 December 2024, using 7 national registers including national HIV and diabetes registers. Follow-up began at T2DM diagnosis. Outcomes included renal events, cardiovascular events, and all-cause mortality. Cox proportional regression estimated hazard ratios (adjHRs) by HIV status, stratified by propensity score quintiles of age, sex, migrant status, comorbidities, and socioeconomics. RESULTS: 350 PWH and 311 668 PWoH were included, with similar median follow-up time (PWH, 7.8 years; PWoH, 8.8 years). PWH had higher renal risk than PWoH (major adverse kidney event: adjHR, 2.04; 95% CI, 1.57-2.65) but no significantly increased cardiovascular risk (major adverse cardiovascular event: adjHR, 1.18; 95% CI, .87-1.60) or all-cause mortality. Findings were consistent across sensitivity analyses, including competing-risk models for death and excluding PWH receiving tenofovir disoproxil fumarate at baseline. Accounting for the benign plasma/serum-creatinine increase associated with bictegravir, cobicistat, dolutegravir, and rilpivirine, the increased renal risk remained, although not statistically significant. The renal risk was most prominent in PWH with BMI ≥30 kg/m2. CONCLUSIONS: In this nationwide cohort, PWH with T2DM exhibited higher risk of renal complications than PWoH, indicating enhanced renal monitoring may be warranted. Further research should investigate underlying mechanisms, including antiretroviral therapy, to guide clinical management.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Killander Möller I, Wagner P, Brännström J, et al. Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024. Clin Infect Dis. 2026. PMID: 41999291. doi:10.1093/cid/ciag261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。